NVO Novo Nordisk A/S

0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing resubmission noted March 29, 2017 in response to CRL issued October 2016.
Fast-acting insulin aspart
Type 1 and type 2 diabetes
Phase 3 completed.
Somapacitan (NN8640)
Adult Growth Hormone Deficiency (AGHD)
Phase 3 trials ongoing as of November 2016.
Oral semaglutide (NN9924)
Type 2 diabetes
Phase 2 data due 2017.
Semaglutide (NN9536)
Phase 2 ongoing.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
Type 2 diabetes
BLA filing announced May 16, 2016. PDUFA estimate May 16, 2017. Advisory Committee Meeting April 4, 2017.
Nonacog beta pegol
haemophilia B

Latest News

  1. 3 Beaten-Up Healthcare Stocks: Are They Bargains?
  2. Citigroup Commercial Mortgage Trust 2017-P7 -- Moody's Assigns Definitive Ratings to Nine CMBS Classes of Citigroup Commercial Mortgage Trust 2017-P7
  3. High-Yield Healthcare Investments You Can Buy Right Now
  4. Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day
  5. Novo Nordisk A/S : NVO-US: Dividend Analysis : March 27th, 2017 (record date) : By the numbers : April 10, 2017
  6. 5 Pharmaceutical Stocks With the Most Reliable Dividends
  7. ($$) The Charms of Bayer and Novo Nordisk
  8. Ailing Novo Seeks Cure With Diabetes Drug Targeting Fat Too
  9. Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 March 2017)
  10. Understanding Sanofi’s Valuation Compared to Peers
  11. Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results
  12. Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion
  13. GlaxoSmithKline’s Valuation Compared to Its Peers
  14. Citigroup Commercial Mortgage Trust 2017-P7 -- Moody's Assigns Provisional Ratings to Nine CMBS Classes of Citigroup Commercial Mortgage Trust 2017-P7
  15. New fast-acting mealtime insulin, Fiasp®, now approved and available in Canada for the treatment of diabetes
  16. 3 Tremendously Promising Diabetes Drugs Potentially on the Way
  17. Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin
  18. Novo’s Basal Insulin Gets CHMP Nod to Update Label
  19. Novo Nordisk’s Hemophilia B Drug Gets CHMP Nod